No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Blue Jet Healthcare Ltd. is a company that focuses on the manufacturing and supply of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), which are critical components for the pharmaceutical and healthcare sectors. Its product offerings include integrated intermediates used in contrast media, saccharin and its associated salts, and a range of specialized pharmaceutical intermediates and APIs. The company also delivers comprehensive contract development and manufacturing (CDMO/CMO) and development services. Founded in 1968, Blue Jet Healthcare is headquartered in Thane, India, and maintains a broad international operational footprint across countries such as India, Norway, the United States, Sweden, Italy, and Spain.
www.bluejethealthcare.comNo one on the platform currently holds BLUEJET.NS.
No tracked institution reports a position in BLUEJET.NS as of their last filing.
No one on the platform has traded BLUEJET.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 16.1% | 26.4% | — | — | — | |
| Rev. Growth % | -8.0% | 13.9% | ||||
| Profit Margin % | 26.2% | 25.6% | ||||
| Free Cash Flow Margin % | 0.0% | 7.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $11.8B | +19.2% | $17.04 | $16.42–$17.83 | — | 4 |
| 2028 | $13.3B | +13.2% | $19.28 | $16.73–$20.97 | — | 5 |
| 2029 | $14.9B | +11.7% | $21.60 | $21.41–$21.79 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $4.23 | $4.53 | +7.1% |
| 2026-05-25 | $2.55 | $3.70 | +45.1% |
| 2026-02-13 | $3.55 | $2.30 | -35.2% |
| 2025-11-04 | $3.25 | $3.00 | -7.7% |
| 2025-08-06 | $6.26 | $5.30 | -15.3% |
| 2025-05-14 | $5.65 | $6.30 | +11.5% |
| 2025-01-29 | $4.10 | $5.70 | +39.0% |
| 2024-10-29 | $3.20 | $3.36 | +5.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| BLUEJET.NSBlue Jet Healthcare Limited | $567.95 | +3.14% | $98.5B | — |
| CONCORDBIO.BOConcord Biotech Limited | $1459.05 | -0.85% | $152.9B | — |
| CONCORDBIO.NSConcord Biotech Limited | $1475.90 | +0.20% | $154.4B | — |
| GRANULES.BOGranules India Limited | $856.75 | -1.81% | $213.3B | — |
| INDGN.BOIndegene Limited |
| $572.35 |
| +0.16% |
| $138.0B |
| — |
| INDGN.NSIndegene Limited | $572.95 | +0.25% | $138.1B | — |
| JUBLINGREA.NSJubilant Ingrevia Limited | $635.65 | +0.82% | $100.3B | — |
Source: Financial Modeling Prep · peers by sector/industry